Unity Biotechnology (UBX) Projected to Post Quarterly Earnings on Tuesday

Unity Biotechnology (NASDAQ:UBX) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter.

Unity Biotechnology (NASDAQ:UBX) last issued its earnings results on Tuesday, April 22nd. The company reported ($0.43) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.43). On average, analysts expect Unity Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Unity Biotechnology Price Performance

Shares of NASDAQ:UBX opened at $0.91 on Friday. The firm has a market capitalization of $15.73 million, a price-to-earnings ratio of -0.70 and a beta of 1.28. The business’s 50 day simple moving average is $1.20 and its 200-day simple moving average is $1.40. Unity Biotechnology has a 12 month low of $0.85 and a 12 month high of $3.10.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Unity Biotechnology in a report on Wednesday, April 23rd. Chardan Capital restated a “buy” rating and set a $4.00 target price on shares of Unity Biotechnology in a report on Wednesday, April 23rd.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.